Skip to main content

Table 2 Gene-level summary P values associated with mammographic density change after quitting EPT use

From: Hormone metabolism pathway genes and mammographic density change after quitting estrogen and progestin combined hormone therapy in the California Teachers Study

Gene

Number of SNPs genotyped

Gene-level association P value *

AKR1C4

1

0.44

AR

6

0.39

ARSC

2

0.02

COMT

21

0.14

CYP11A

12

0.64

CYP19A1

2

0.80

CYP1A1/CYP1A2

5

0.97

CYP1B1

15

0.61

CYP21A2

2

0.13

CYP2C9

16

0.73

CYP3A4

3

0.46

ESR1

13

0.81

ESR2

22

0.68

HSD17B1

5

0.11

HSD17B2

24

>0.99

HSD17B4

24

0.49

HSD17B5/AKR1C3

38

0.85

HSD3B1

4

0.14

HSD3B2

10

0.97

PGR

32

0.81

SHBG

13

0.60

SLCO1B1 (SLC21A6)

38

0.04

SRD5A1

24

0.80

SULT1A1/SULT1A2

6

0.26

SULT1E1

18

0.50

UGT1A8

43

0.99

UGT2B17

1

0.63

UGT2B7

5

0.52

  1. *Based on the adaptive rank truncated product (ARTP) statistics. EPT, estrogen and progestin combined therapy; SNP, single nucleotide polymorphisms.